Residency · Residency · Family Medicine

Menopause Management and Hormone Therapy

Overview

Menopause is defined as 12 consecutive months of amenorrhea in the absence of other causes, typically occurring at a mean age of 51. The menopause transition, or perimenopause, begins years earlier with hormonal fluctuations. Family physicians play a central role in managing vasomotor symptoms, genitourinary syndrome of menopause, bone health, and cardiovascular risk during this transition.

Definitions and Diagnosis

Perimenopause is characterized by irregular cycles, vasomotor symptoms, and hormonal variability, and it can last 4 to 8 years before the final menstrual period. Menopause itself is a retrospective diagnosis made after 12 months of amenorrhea, and laboratory testing is not required in women over 45 with classic symptoms. Premature ovarian insufficiency denotes menopause before age 40 and requires hormone therapy until at least age 51 to protect bone and cardiovascular health. FSH and estradiol levels are not routinely needed for diagnosis in typical presentations, though FSH may be helpful in situations of diagnostic uncertainty such as post-hysterectomy, age under 45, or concurrent hormonal contraception use.

Vasomotor Symptoms (VMS)

Hot flashes and night sweats affect up to 80% of menopausal women. The median duration is 7.4 years, though symptoms can persist beyond 10 years in some women. Severity ranges from a mild sensation of heat to drenching sweats with sleep disruption and significantly impaired quality of life. Higher BMI, smoking, Black race, and anxiety are associated with more severe and prolonged vasomotor symptoms.

Non-Pharmacologic Management

Non-pharmacologic strategies include layered clothing, cooling pillows, and fan use. Cognitive behavioral therapy and clinical hypnosis have randomized controlled trial evidence supporting their use for VMS reduction. Weight loss in overweight women may reduce symptom burden. Exercise provides general health benefits but has limited evidence for VMS specifically. Avoidance of individual triggers such as alcohol, spicy food, and caffeine may help selected patients.

Hormone Therapy (HT)

Indications

Vasomotor symptoms are the primary indication for systemic hormone therapy, which is the most effective treatment available, reducing hot flash frequency by approximately 75%. Hormone therapy also benefits bone density, joint pain, sleep, and mood during the menopause transition.

Types and Routes

Estrogen-only therapy is appropriate for women without a uterus and is available as conjugated equine estrogen, oral estradiol, and transdermal estradiol in patch, gel, and spray formulations. Combined estrogen-progestogen therapy is mandatory for women with a uterus to prevent endometrial hyperplasia and cancer. This can be administered as continuous combined therapy with daily estrogen plus daily progestogen, producing no withdrawal bleeding, or as cyclic or sequential therapy with daily estrogen plus progestogen for 12 to 14 days per month, resulting in withdrawal bleeding. Among progestogen options, micronized progesterone (Prometrium) is preferred for its favorable metabolic profile. Medroxyprogesterone acetate (Provera) is another option, and the levonorgestrel IUD provides effective endometrial protection off-label. Transdermal estrogen is preferred over oral formulations in women with elevated VTE risk, hypertriglyceridemia, migraine with aura, or hepatic disease because it avoids first-pass hepatic metabolism. Bazedoxifene combined with conjugated estrogen (Duavee) is a tissue-selective estrogen complex that does not require additional progestogen.

Timing and the "Window of Opportunity"

Hormone therapy should ideally be initiated within 10 years of menopause onset or before age 60 for the optimal benefit-risk profile. Within this window, the cardiovascular effect is either beneficial or neutral. After age 60 or more than 10 years post-menopause, the risks of cardiovascular disease and VTE increase, and systemic hormone therapy should not be initiated. There is no mandatory duration limit for hormone therapy use; benefits and risks should be reassessed annually, and many women benefit from continued use.

Risks

Oral estrogen increases VTE risk approximately 2-fold, though transdermal estrogen does not significantly increase this risk. Combined estrogen-progestogen therapy slightly increases breast cancer risk after 3 to 5 years of use, with a relative risk of approximately 1.24, while estrogen-only therapy may have a neutral or slightly protective effect. There is a small absolute increase in stroke risk with oral estrogen, though transdermal low-dose formulations may not increase this risk. Gallbladder disease risk is increased with oral estrogen.

Contraindications

Contraindications to hormone therapy include unexplained vaginal bleeding, active or history of breast cancer, active liver disease, history of VTE or known thrombophilia (a relative contraindication where transdermal may be acceptable), active coronary heart disease or stroke, and known pregnancy.

Non-Hormonal Pharmacotherapy for VMS

Fezolinetant (Veozah) is an NK3 receptor antagonist FDA-approved in 2023 that reduces moderate to severe VMS by approximately 60%, though liver function tests require monitoring. Among SSRIs and SNRIs, paroxetine (Brisdelle) at 7.5 mg is the only FDA-approved SSRI for VMS, while venlafaxine, desvenlafaxine, and escitalopram are used off-label. Gabapentin at 300 to 900 mg at bedtime is particularly helpful for nocturnal VMS. Clonidine has a modest effect but is limited by side effects including hypotension and dry mouth. Oxybutynin has emerging evidence for VMS reduction but is used off-label.

Genitourinary Syndrome of Menopause (GSM)

GSM encompasses vaginal dryness, dyspareunia, urinary urgency and frequency, and recurrent UTI. It affects up to 50% of postmenopausal women and, unlike vasomotor symptoms, does not improve without treatment but instead progressively worsens over time.

Treatment

First-line management includes vaginal moisturizers applied regularly and lubricants used during intercourse. Low-dose vaginal estrogen, available as cream, tablet (Vagifem), or ring (Estring), is highly effective with minimal systemic absorption. It is safe in most women, including many breast cancer survivors, though discussion with oncology is recommended in that setting. Importantly, progestogen supplementation is not needed with low-dose vaginal estrogen. Ospemifene (Osphena) is an oral SERM indicated for dyspareunia and serves as an alternative for women who cannot use vaginal estrogen. Prasterone (Intrarosa) is a vaginal DHEA insert that converts locally to estrogen and testosterone. Vaginal laser therapy has limited evidence, is not FDA-approved for GSM, and is not recommended by professional societies outside of clinical trials.

Bone Health in Menopause

Accelerated bone loss occurs in the 5 to 7 years surrounding menopause. DEXA screening is recommended at age 65, or earlier in the presence of risk factors such as premature ovarian insufficiency, glucocorticoid use, fracture history, or low BMI. Hormone therapy is effective for fracture prevention but is not recommended as the sole indication for osteoporosis treatment. Patients transitioning off hormone therapy should be started on a bisphosphonate or other osteoporosis therapy.

Cardiovascular Considerations

Cardiovascular disease risk increases after menopause with the loss of estrogen's cardioprotective effects, necessitating aggressive lipid and blood pressure management. Hormone therapy initiated within the window of opportunity may have cardioprotective effects, but this does not constitute an indication to start hormone therapy solely for cardiovascular disease prevention.

Mood and Cognitive Symptoms

Perimenopause is a vulnerable period for new-onset or recurrent depression. Hormone therapy may improve depressive symptoms during perimenopause but not during the postmenopausal period. Hormone therapy is not indicated for dementia prevention; the WHI showed no cognitive benefit and possible harm when hormone therapy was started after age 65.

<image>A decision algorithm for vasomotor symptom management showing first-line assessment of severity, then branching into non-pharmacologic interventions, hormone therapy (with sub-branches for estrogen-only vs. combined, oral vs. transdermal based on risk factors), and non-hormonal alternatives (fezolinetant, SSRIs/SNRIs, gabapentin) for women with contraindications to HT.</image>

<image>A comparison table of hormone therapy formulations showing route of administration (oral, transdermal patch, gel, spray, vaginal), estrogen type, progestogen options, relative VTE risk, and clinical scenarios favoring each formulation. Include a highlighted section on the timing hypothesis with the 10-year window of opportunity.</image>

<image>An anatomical diagram illustrating genitourinary syndrome of menopause showing the effects of estrogen deficiency on vaginal epithelium (thinning, decreased rugae, increased pH), urethral tissue, and pelvic floor, with annotations linking tissue changes to clinical symptoms (dryness, dyspareunia, urgency, recurrent UTI).</image>

Clinical Pearls

Menopause is a clinical diagnosis in women over 45 with amenorrhea and symptoms, and routine laboratory testing is usually unnecessary. Transdermal estrogen is preferred over oral formulations in women with cardiovascular risk factors, obesity, migraine with aura, or VTE risk because it avoids first-pass hepatic metabolism. Micronized progesterone has a more favorable metabolic and breast cancer risk profile compared to medroxyprogesterone acetate. GSM is progressive and will not resolve spontaneously; low-dose vaginal estrogen is safe and effective, even in many breast cancer survivors. The WHI findings must be interpreted in context, as participants had a mean age of 63, well outside the window of opportunity, and predominantly used oral conjugated equine estrogen plus MPA. Fezolinetant is a new non-hormonal option for VMS with efficacy approaching that of hormone therapy, though it requires liver function monitoring. There is no mandatory time limit for hormone therapy use; benefits and risks should be reassessed annually through shared decision-making. Premature ovarian insufficiency requires hormone therapy until at least the natural age of menopause at 51 to prevent osteoporosis and cardiovascular disease.

References

• The NAMS 2022 Hormone Therapy Position Statement. Menopause. 2022
• USPSTF Recommendation on Hormone Therapy for Prevention of Chronic Conditions in Postmenopausal Women. JAMA. 2022
• Stuenkel CA et al. Treatment of Symptoms of the Menopause: Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015
• Manson JE et al. Menopausal Hormone Therapy and Long-Term All-Cause and Cause-Specific Mortality: WHI Randomized Trials. JAMA. 2017
• Johnson KA et al. Fezolinetant for Vasomotor Symptoms of Menopause. N Engl J Med. 2023

Read this lecture as Markdown